LCI [NYSE]
Lannett Company, Inc.
Index- P/E- EPS (ttm)-7.93 Insider Own8.70% Shs Outstand40.50M Perf Week-3.32%
Market Cap25.81M Forward P/E- EPS next Y-1.32 Insider Trans4.30% Shs Float37.24M Perf Month11.58%
Income-316.20M PEG- EPS next Q-0.46 Inst Own52.70% Short Float12.27% Perf Quarter-29.32%
Sales372.40M P/S0.07 EPS this Y-967.30% Inst Trans-13.26% Short Ratio14.09 Perf Half Y-65.67%
Book/sh-3.93 P/B- EPS next Y14.30% ROA-49.80% Target Price2.25 Perf Year-87.58%
Cash/sh2.39 P/C0.24 EPS next 5Y15.00% ROE351.10% 52W Range0.45 - 4.98 Perf YTD-64.19%
Dividend- P/FCF1.02 EPS past 5Y-57.50% ROI-54.70% 52W High-88.63% Beta1.00
Dividend %- Quick Ratio2.40 Sales past 5Y-3.30% Gross Margin12.90% 52W Low25.67% ATR0.07
Employees812 Current Ratio3.40 Sales Q/Q-30.20% Oper. Margin-35.50% RSI (14)47.48 Volatility8.70% 14.90%
OptionableYes Debt/Eq- EPS Q/Q-376.70% Profit Margin-84.90% Rel Volume0.31 Prev Close0.58
ShortableYes LT Debt/Eq- EarningsMay 04 AMC Payout- Avg Volume324.51K Price0.57
Recom3.00 SMA20-3.27% SMA50-1.71% SMA200-59.62% Volume88,704 Change-2.42%
Mar-20-19Initiated SunTrust Hold
Aug-20-18Downgrade ROTH Capital Buy → Neutral
Aug-20-18Downgrade Raymond James Outperform → Mkt Perform
Jan-24-18Initiated Goldman Neutral
Jun-29-16Initiated Deutsche Bank Hold $26
Mar-24-16Downgrade Canaccord Genuity Buy → Sell $28 → $18
Feb-04-16Upgrade Craig Hallum Hold → Buy
Nov-05-15Downgrade Craig Hallum Buy → Hold
Sep-03-15Reiterated ROTH Capital Buy $61 → $68
Jul-21-15Initiated Susquehanna Positive
Feb-05-15Reiterated ROTH Capital Buy $54 → $61
Nov-24-14Reiterated ROTH Capital Buy $66 → $60
Nov-04-14Reiterated ROTH Capital Buy $53 → $66
Nov-04-14Reiterated Canaccord Genuity Buy $55 → $73
Nov-04-14Downgrade Oppenheimer Outperform → Perform $53
Oct-13-14Reiterated Oppenheimer Outperform $51 → $53
Jul-15-14Reiterated Oppenheimer Outperform $49 → $52
May-06-14Resumed Canaccord Genuity Buy $55
Feb-10-14Reiterated Canaccord Genuity Buy $29 → $55
Feb-07-14Reiterated Oppenheimer Outperform $41 → $45
Jun-01-22 06:52AM  
May-12-22 11:02AM  
06:52AM  
May-04-22 07:35PM  
04:15PM  
Apr-27-22 06:52AM  
Mar-29-22 06:52AM  
Mar-18-22 04:15PM  
Mar-07-22 12:39PM  
Mar-04-22 05:33PM  
04:15PM  
02:34PM  
06:52AM  
Feb-05-22 08:10AM  
Feb-03-22 06:25PM  
04:15PM  
Jan-27-22 06:52AM  
Jan-26-22 03:01PM  
Jan-21-22 06:52AM  
Dec-20-21 06:52AM  
Nov-03-21 07:55PM  
07:31PM  
04:15PM  
Oct-28-21 06:52AM  
Oct-27-21 03:03PM  
Sep-10-21 09:44AM  
Aug-30-21 11:56AM  
07:47AM  
06:52AM  
Aug-26-21 05:00AM  
Aug-25-21 04:15PM  
Aug-18-21 06:52AM  
Aug-04-21 09:34AM  
Jul-29-21 06:52AM  
Jul-12-21 06:52AM  
Jun-09-21 03:25AM  
Jun-01-21 06:52AM  
May-28-21 05:39PM  
May-27-21 05:47PM  
May-06-21 01:01AM  
May-05-21 08:05PM  
04:15PM  
02:30PM  
08:37AM  
Apr-28-21 12:33PM  
06:53AM  
Apr-22-21 04:15PM  
Apr-09-21 06:52AM  
Apr-06-21 08:12AM  
07:21AM  
Apr-01-21 08:30AM  
Mar-21-21 09:14PM  
Mar-18-21 05:25PM  
Mar-16-21 09:35PM  
Mar-14-21 10:31PM  
Mar-12-21 06:25AM  
Mar-10-21 07:48AM  
06:52AM  
Mar-09-21 10:58PM  
Mar-07-21 02:39PM  
Mar-03-21 03:00AM  
Feb-22-21 02:04PM  
Feb-20-21 06:30PM  
Feb-19-21 01:15AM  
Feb-15-21 10:16PM  
Feb-13-21 02:40PM  
Feb-11-21 01:35PM  
Feb-09-21 06:53AM  
Feb-08-21 07:10PM  
06:52AM  
Feb-06-21 11:09PM  
Feb-04-21 01:33PM  
Feb-03-21 09:31PM  
06:05PM  
05:39PM  
04:15PM  
02:45PM  
Jan-27-21 06:52AM  
Dec-15-20 10:48AM  
Dec-10-20 09:24PM  
Dec-07-20 05:42PM  
04:15PM  
Nov-30-20 06:52AM  
Nov-06-20 07:38AM  
Nov-04-20 08:31PM  
07:55PM  
04:15PM  
02:30PM  
08:58AM  
Nov-03-20 06:52AM  
Oct-28-20 12:32PM  
06:53AM  
Aug-27-20 06:07AM  
Aug-26-20 08:30PM  
05:14PM  
04:15PM  
Aug-25-20 10:14AM  
Aug-19-20 06:52AM  
Aug-17-20 04:30PM  
06:52AM  
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Group of companies, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEPORE PATRICK GDirectorMay 16Buy0.5450,00027,000487,145May 17 04:16 PM
FARBER JEFFREYDirectorMar 17Buy0.8120,00016,2002,152,454Mar 21 04:26 PM
Israel Samuel HChief Legal OfficerFeb 15Buy0.8112,0009,720175,453Feb 15 05:45 PM
Chapman John CDirectorFeb 11Buy0.8012,50010,000154,324Feb 15 05:46 PM
Abt JohnChief Quality and OperationsFeb 10Buy0.905,0004,500128,815Feb 11 04:31 PM
FARBER JEFFREYDirectorFeb 09Buy0.9210,0009,2002,132,454Feb 10 05:16 PM
LEPORE PATRICK GDirectorFeb 08Buy0.8850,00044,000437,145Feb 10 05:17 PM
KOZLOWSKI JOHNVP of Finance & CFODec 14Buy1.814,9008,869157,494Dec 14 04:26 PM
Crew Timothy CChief Executive OfficerDec 13Buy1.9920,00039,800584,270Dec 14 04:25 PM
KOZLOWSKI JOHNVP of Finance & CFODec 02Buy1.684,0006,720152,594Dec 02 04:18 PM
LEPORE PATRICK GDirectorNov 29Buy1.7150,00085,500387,145Nov 30 04:05 PM
FARBER JEFFREYDirectorNov 17Buy1.9310,00019,3002,122,454Dec 01 04:42 PM
KOZLOWSKI JOHNVP of Finance & CFONov 16Buy2.067,00014,420148,594Nov 16 04:13 PM
Rewolinski MelissaDirectorSep 09Sale3.1825,34080,58162,100Sep 13 04:09 PM
LEPORE PATRICK GDirectorSep 08Buy3.3120,00066,200337,145Sep 09 04:07 PM